1. Home
  2. BMEA vs UBXG Comparison

BMEA vs UBXG Comparison

Compare BMEA & UBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMEA
  • UBXG
  • Stock Information
  • Founded
  • BMEA 2017
  • UBXG 2018
  • Country
  • BMEA United States
  • UBXG China
  • Employees
  • BMEA N/A
  • UBXG N/A
  • Industry
  • BMEA Biotechnology: Pharmaceutical Preparations
  • UBXG
  • Sector
  • BMEA Health Care
  • UBXG
  • Exchange
  • BMEA Nasdaq
  • UBXG Nasdaq
  • Market Cap
  • BMEA 65.8M
  • UBXG 67.8M
  • IPO Year
  • BMEA 2021
  • UBXG 2024
  • Fundamental
  • Price
  • BMEA $1.57
  • UBXG $2.94
  • Analyst Decision
  • BMEA Strong Buy
  • UBXG
  • Analyst Count
  • BMEA 10
  • UBXG 0
  • Target Price
  • BMEA $21.00
  • UBXG N/A
  • AVG Volume (30 Days)
  • BMEA 957.5K
  • UBXG 18.5K
  • Earning Date
  • BMEA 08-12-2025
  • UBXG 01-01-0001
  • Dividend Yield
  • BMEA N/A
  • UBXG N/A
  • EPS Growth
  • BMEA N/A
  • UBXG N/A
  • EPS
  • BMEA N/A
  • UBXG N/A
  • Revenue
  • BMEA N/A
  • UBXG $39,603,353.00
  • Revenue This Year
  • BMEA N/A
  • UBXG N/A
  • Revenue Next Year
  • BMEA N/A
  • UBXG N/A
  • P/E Ratio
  • BMEA N/A
  • UBXG N/A
  • Revenue Growth
  • BMEA N/A
  • UBXG N/A
  • 52 Week Low
  • BMEA $1.29
  • UBXG $2.36
  • 52 Week High
  • BMEA $13.07
  • UBXG $567.04
  • Technical
  • Relative Strength Index (RSI)
  • BMEA 37.40
  • UBXG N/A
  • Support Level
  • BMEA $1.72
  • UBXG N/A
  • Resistance Level
  • BMEA $1.75
  • UBXG N/A
  • Average True Range (ATR)
  • BMEA 0.11
  • UBXG 0.00
  • MACD
  • BMEA -0.02
  • UBXG 0.00
  • Stochastic Oscillator
  • BMEA 9.20
  • UBXG 0.00

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About UBXG U-BX Technology Ltd. Ordinary Shares

U-BX Technology Ltd is focused on providing value-added services using artificial intelligence-driven technology to businesses within the insurance industry, including insurance carriers and brokers. It helps institutional clients obtain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or its clients' promotion time through those channels. The company derives a majority of its revenue by providing digital promotion services to its clients and also engages in providing risk assessment services, and value-added bundled benefits. It has developed an algorithm named Magic Mirror, to calculate payout risks for insurance carriers to underwrite auto insurance coverage. Geographically, all of the company's revenue is derived from Mainland China.

Share on Social Networks: